Skip to main content
UCB's Global Corporate Website
instagram
facebook
twitter
youtube
linkedin
rss
Listen
19 Dec 2016
Transparency notification
Read More
19 Dec 2016
UCB and Amgen announce submission of application for investigational osteoporosis medication romosozumab in Japan
Read More
19 Dec 2016
UCB’s anti-epileptic drug VIMPAT® (lacosamide) approved as monotherapy by European Commission
Read More
15 Dec 2016
Transparency notification
Read More
14 Dec 2016
New appointments on UCB's Board of Directors
Read More
7 Dec 2016
Second CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
Read More
7 Dec 2016
Transparency notifications
Read More
2 Dec 2016
UCB highlights epilepsy research at the 2016 American Epilepsy Society Annual Meeting
Read More
2 Dec 2016
Transparency notification
Read More
17 Nov 2016
Transparency notification
Read More
Pagination
First page
Previous page
‹ Previous
…
Page
35
Page
36
Page
37
Page
38
Current page
39
Page
40
Page
41
Page
42
Page
43
…
Next page
Next ›
Last page
Subscribe to
Choose a Country
Global Site – English
Australia – English
België – Engels
Belgique – Anglais
Brasil – Português
България – Български
Canada – English
Canada – Français
中国 – 中文
Česká Republika – Angličtina
Danmark – Engelsk
Deutschland – Deutsch
France – Français
España – Español
Ελλάδα – Ελληνικά
India – English
Ireland – English
Italia – Inglese
日本 – 日本語
한국 – 한국어
Luxembourg – Anglais
Luxemburg – Engels
Magyarország – Angol
México & Latinoamérica – Español
Nederland – Engels
New Zealand – English
Norge – Engelsk
Österreich – Deutsch
Polska – Polski
Portugal – español y portugués
România – Engleză
Россия – Русский
Slovensko – Anglický
Suomi – Englanti
Sverige – Engelska
Schweiz – Deutsch
Türkiye – Türkçe
Україна – Англійська
United Kingdom – English
U.S.A. – English
×
instagram
facebook
twitter
youtube
linkedin
rss